Bridging Biotech Between China and the West
We enable cross-border biotech partnerships, helping Chinese innovators reach global markets and Western innovators succeed in China.
The Innovator’s Dilemma
China is one of the fastest-growing biotech markets, offering breakthrough innovation at scale. Yet complex regulations, uncertain pathways, and global headwinds often slow or stall collaborations. Making successful cross-border biotech partnerships challenging. Success requires more than a partner. It requires on-the-ground expertise.
For Western biotechs, this means trusted local insight; for Chinese innovators, it means navigating FDA/EMA standards and connecting with the right global partners. At SEQOVA, we bridge both worlds, turning barriers into opportunities for growth.
The SEQOVA DNA
Tailored solutions for two worlds of innovators.
For Chinese Innovators:
Going Global
Navigate Global Regulatory Pathways: Position assets for FDA and EMA compliance with confidence, from Proof of Concept (PoC) to New Drug Application (NDA).
Structure Deals & Partnerships: Out-license, co-develop, to maximise value and accelerate growth.
Connect with Strategic Partners: Access trusted Western pharma and biotech networks to expand global reach.
For Western Innovators: Succeeding in China
Strategic Asset Sourcing: Identify the right Chinese innovations that complement your pipeline, increase valuation, and strengthen your platform.
Licensing & Acquisition Support: Align with the best partners to create high-value, low-risk deals that accelerate market entry.
Partnership Enablement: Bring together trusted Chinese innovators and expert teams to ensure long-term growth, credibility, and operational success.
The SEQOVA Advantage
At SEQOVA, we combine access, insight, and execution to unlock opportunities that others overlook.
Partnering for the Future
SEQOVA doesn’t just advise.
We lead and structure transformative opportunities, aligning the right assets with the right partners to create value.

